<p>結合以加速藥品福利管理行業的轉型，徹底改變更廣泛的醫療體驗</p>
<p>, /PRNewswire/ -- Abarca Health 和 LucyRx 今天宣佈進行戰略合併，創建唯一一家現代化、獨立的藥品福利管理公司，具備規模、技術和業績記錄，能夠可信地為任何規模的商業和政府客户提供服務。合併後，Abarca 和 LucyRx 將為美國超過 900 萬名會員提供處方服務。</p>
<p>這一時機是經過深思熟慮的。藥品福利管理市場正處於一個臨界點，受到新的監管範式、高成本特藥和 GLP-1 的持續壓力，以及客户對不同類型藥品福利管理關係的需求——這種關係提供更多靈活性、真正的問責制和可持續的可負擔性。僱主、消費者和醫療服務提供者理應享有更好的體驗。</p>
<p>&#34;利用我們合併後的規模、技術和業績記錄，我們將加速 Abarca 在 20 多年前發起的醫療革命，&#34; LucyRx 首席執行官 David Blair 説道。&#34;我們將共同提供一個值得信賴的運營基礎，量身定製的客户體驗，依託一流的技術，以及以患者為中心的整體護理成本節省。&#34;</p>
<p>支撐這一戰略合併的是 Abarca 的 Darwin Healthcare Intelligence 平台——專為多樣化和不斷發展的支付方需求而構建，對於協調更好的護理、降低福利和行政成本、以及賦予客户和會員選擇權至關重要。</p>
<p>&#34;LucyRx 與我們的願景一致，旨在讓每個人的醫療體驗更加無縫和個性化，&#34; Abarca Health 首席執行官 Jason Borschow 説道。&#34;我們期待利用 LucyRx 的臨牀能力、連接的特藥護理網絡，以及為全國僱主和工會服務的專業知識，深化我們的服務產品，並加速進入新的市場領域。&#34;</p>
<p>持續性仍然是首要任務。客户和會員將不會經歷任何中斷，日常執行將繼續由相同的團隊、標準、響應能力和賬户關係進行。兩個品牌將繼續存在，並在交易完成後作為 Healthcare Revolution Partners 的全資子公司運營。每家公司將繼續專注於其核心市場。LucyRx 將繼續發揮其在僱主和第三方管理機構服務方面的優勢，而 Abarca 將繼續在健康計劃和政府項目中保持領先。領導層將保持不變，Blair 和 Borschow 將繼續擔任各自公司的首席執行官，並在交易完成後共同擔任 Healthcare Revolution Partners 的聯合主席。</p>
<p>Healthcare Revolution Partners 將是一個以使命為導向的志同道合組織的聯盟，致力於加速處方護理的更好方式，並徹底改變更廣泛的醫療體驗。合併後的實體將為市場帶來獨特的行業領先技術、數十年的運營專業知識，以及不懈的承諾，以規模化提供更好的體驗。</p>
<p>&#34;我們團結在一起，相信通過合作，我們將使醫療服務對每個人都變得無縫和個性化，&#34; Blair 和 Borschow 總結道。</p>
<p>該交易需經監管批准和慣例成交條件。各方在交易完成之前仍然獨立擁有和運營，預計交易將在 2026 年第三季度完成。</p>
<p>欲瞭解更多信息，請訪問 acceleratetherevolution.com。</p>
<p><strong>關於 Abarca Health</strong> 在 Abarca，我們看到一個醫療服務無縫且個性化的未來，我們每天都在努力使其成為我們服務的個人和組織的現實。我們從處方開始，這是醫療服務的前線。但通過利用我們更智能的技術、簡單明瞭的商業模式，以及一個致力於創新和尋找更好方法的團隊，我們正在推動更廣泛的醫療革命。瞭解更多信息，請訪問 abarcahealth.com。</p>
<p><strong>關於 LucyRx</strong> LucyRx 是一家快速擴張的獨立下一代藥品福利管理公司，重新定義處方護理。憑藉其全國認可的臨牀能力和專有平台 LucyIQ™，該公司提供實時洞察，支持基於證據的臨牀決策、清晰的定價和來自美國認證藥劑師的卓越服務。與超過 60,000 家藥房合作，LucyRx 在全國服務超過 4,000 家客户。這是經過精彩重新構想的處方護理。欲瞭解更多信息，請訪問 lucyrx.com。</p>
<p><strong>顧問</strong> 摩根士丹利 &amp; Co. LLC 擔任 Abarca Health 的財務顧問。Pietrantoni Mendez &amp; Alvarez, LLC 擔任首席法律顧問，Axinn Veltrop &amp; Harkrider LLP 擔任 Abarca Health 的監管顧問。</p>
<p>Great Meadows Management, LLC 擔任 LucyRx 的首席財務顧問。Kirkland &amp; Ellis, LLP 和 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 擔任 LucyRx 的法律顧問。</p>
<p>來源 LucyRx; Abarca Health</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE3Jk5ld3NJdGVtSWQ9UEg4NjIwMCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTcxNDE4UFJfTkVXU19VU1BSX19fX19QSDg2MjAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE3Jk5ld3NJdGVtSWQ9UEg4NjIwMCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTcxNDE4UFJfTkVXU19VU1BSX19fX19QSDg2MjAw"/></p>

<p>Abarca Health 和 LucyRx 宣佈進行戰略合併，創建一個現代化的獨立藥品福利管理公司（PBM），為超過 900 萬會員提供服務。此次合併旨在通過利用合併後的技術和規模來應對監管變化和高藥品成本。兩個品牌將作為 Healthcare Revolution Partners 的子公司運營，領導層保持不變。該交易需獲得監管批准，預計將在 2026 年第三季度完成</p>

<p>Combining to accelerate PBM industry transformation and revolutionize the broader healthcare experience</p>
<div class="lb-trans"><p>結合以加速藥品福利管理行業的轉型，徹底改變更廣泛的醫療體驗</p>
</div><p>, /PRNewswire/ -- Abarca Health and LucyRx today announced a strategic combination to create the only modern, independent pharmacy benefit manager with the scale, technology, and track record to credibly serve commercial and government clients of any size. Combined, Abarca and LucyRx will provide prescription services to more than 9 million members across the United States.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Abarca Health 和 LucyRx 今天宣佈進行戰略合併，創建唯一一家現代化、獨立的藥品福利管理公司，具備規模、技術和業績記錄，能夠可信地為任何規模的商業和政府客户提供服務。合併後，Abarca 和 LucyRx 將為美國超過 900 萬名會員提供處方服務。</p>
</div><p>The timing is intentional. The PBM market is at a breaking point shaped by a new regulatory paradigm, sustained pressure from high-cost specialty drugs and GLP-1s, and clients demanding a different kind of PBM relationship—one that delivers more flexibility, true accountability, and sustainable affordability. Employers, consumers, and healthcare providers deserve a better experience.</p>
<div class="lb-trans"><p>這一時機是經過深思熟慮的。藥品福利管理市場正處於一個臨界點，受到新的監管範式、高成本特藥和 GLP-1 的持續壓力，以及客户對不同類型藥品福利管理關係的需求——這種關係提供更多靈活性、真正的問責制和可持續的可負擔性。僱主、消費者和醫療服務提供者理應享有更好的體驗。</p>
</div><p>&#34;Leveraging our combined scale, technology, and track record, we will accelerate the healthcare revolution Abarca started more than 20 years ago,&#34; said David Blair, Chief Executive Officer of LucyRx. &#34;Together, we will deliver a trusted operating foundation, tailored customer experiences powered by best-in-class technology, and total-cost-of-care savings anchored in putting patients first.&#34;</p>
<div class="lb-trans"><p>&#34;利用我們合併後的規模、技術和業績記錄，我們將加速 Abarca 在 20 多年前發起的醫療革命，&#34; LucyRx 首席執行官 David Blair 説道。&#34;我們將共同提供一個值得信賴的運營基礎，量身定製的客户體驗，依託一流的技術，以及以患者為中心的整體護理成本節省。&#34;</p>
</div><p>Underpinning the strategic combination is Abarca's Darwin Healthcare Intelligence platform – purpose built for diverse and evolving payer needs and critical for coordinating better care, lowering benefit and administrative costs, and empowering choice for clients and members.</p>
<div class="lb-trans"><p>支撐這一戰略合併的是 Abarca 的 Darwin Healthcare Intelligence 平台——專為多樣化和不斷發展的支付方需求而構建，對於協調更好的護理、降低福利和行政成本、以及賦予客户和會員選擇權至關重要。</p>
</div><p>&#34;LucyRx shares our vision of making healthcare more seamless and personalized for everyone,&#34; said Jason Borschow, Chief Executive Officer of Abarca Health. &#34;We look forward to leveraging LucyRx's clinical capabilities, Connected Specialty Care Network, and expertise serving employers and labor groups nationwide to deepen our service offerings and accelerate our entry into new market segments.&#34;</p>
<div class="lb-trans"><p>&#34;LucyRx 與我們的願景一致，旨在讓每個人的醫療體驗更加無縫和個性化，&#34; Abarca Health 首席執行官 Jason Borschow 説道。&#34;我們期待利用 LucyRx 的臨牀能力、連接的特藥護理網絡，以及為全國僱主和工會服務的專業知識，深化我們的服務產品，並加速進入新的市場領域。&#34;</p>
</div><p>Continuity remains the top priority. Clients and members will experience no disruption as day-to-day execution continues with the same teams, standards, responsiveness, and account relationships continuing as they do today. Both brands will remain in place, and at closing, operate as wholly owned subsidiaries of Healthcare Revolution Partners. Each company will remain focused on its core markets. LucyRx will continue to build on its strengths serving employers and TPAs, and Abarca will continue to lead in health plans and government programs. Leadership will remain unchanged, with Blair and Borschow continuing to serve as CEOs of their respective companies and joining Healthcare Revolution Partners as Co-Chairs at closing.</p>
<div class="lb-trans"><p>持續性仍然是首要任務。客户和會員將不會經歷任何中斷，日常執行將繼續由相同的團隊、標準、響應能力和賬户關係進行。兩個品牌將繼續存在，並在交易完成後作為 Healthcare Revolution Partners 的全資子公司運營。每家公司將繼續專注於其核心市場。LucyRx 將繼續發揮其在僱主和第三方管理機構服務方面的優勢，而 Abarca 將繼續在健康計劃和政府項目中保持領先。領導層將保持不變，Blair 和 Borschow 將繼續擔任各自公司的首席執行官，並在交易完成後共同擔任 Healthcare Revolution Partners 的聯合主席。</p>
</div><p>Healthcare Revolution Partners will be a mission-led union of like-minded organizations working to accelerate a better way in prescription care and revolutionize the broader healthcare experience. The combined entity will bring to the market a unique combination of industry-leading technology, decades of operating expertise, and an unstoppable commitment to deliver a better experience at scale.</p>
<div class="lb-trans"><p>Healthcare Revolution Partners 將是一個以使命為導向的志同道合組織的聯盟，致力於加速處方護理的更好方式，並徹底改變更廣泛的醫療體驗。合併後的實體將為市場帶來獨特的行業領先技術、數十年的運營專業知識，以及不懈的承諾，以規模化提供更好的體驗。</p>
</div><p>&#34;We are united by the belief that, by working together, we will make healthcare seamless and personalized for everyone,&#34; concluded Blair and Borschow.</p>
<div class="lb-trans"><p>&#34;我們團結在一起，相信通過合作，我們將使醫療服務對每個人都變得無縫和個性化，&#34; Blair 和 Borschow 總結道。</p>
</div><p>The transaction is subject to regulatory approvals and customary closing conditions. The parties remain independently owned and operated until the transaction closes, which is expected in the third quarter of 2026.</p>
<div class="lb-trans"><p>該交易需經監管批准和慣例成交條件。各方在交易完成之前仍然獨立擁有和運營，預計交易將在 2026 年第三季度完成。</p>
</div><p>For more information, visit acceleratetherevolution.com.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 acceleratetherevolution.com。</p>
</div><p><strong>About Abarca Health</strong> At Abarca, we see a future in which healthcare is seamless and personalized, and we are working every day to make it a reality for the people and organizations we serve. We are starting with prescriptions, the frontline of healthcare. But, leveraging our smarter technology, straightforward approach to business, and a team that is driven to innovate and find a better way in everything we do, we are enabling a broader healthcare revolution. Learn more at abarcahealth.com</p>
<div class="lb-trans"><p><strong>關於 Abarca Health</strong> 在 Abarca，我們看到一個醫療服務無縫且個性化的未來，我們每天都在努力使其成為我們服務的個人和組織的現實。我們從處方開始，這是醫療服務的前線。但通過利用我們更智能的技術、簡單明瞭的商業模式，以及一個致力於創新和尋找更好方法的團隊，我們正在推動更廣泛的醫療革命。瞭解更多信息，請訪問 abarcahealth.com。</p>
</div><p><strong>About LucyRx</strong> LucyRx is a fast-scaling, independent, next-generation pharmacy benefit manager (PBM) redefining prescription care. Fueled by its nationally recognized clinical capabilities and proprietary platform, LucyIQ™, the company provides real-time insights that support evidence-based clinical decisions, clear pricing, and exceptional service from U.S.-based certified pharmacy technicians. Partnering with more than 60,000 pharmacies, LucyRx serves more than 4,000 clients nationwide. This is prescription care, brilliantly reimagined. Visit lucyrx.com for more information.</p>
<div class="lb-trans"><p><strong>關於 LucyRx</strong> LucyRx 是一家快速擴張的獨立下一代藥品福利管理公司，重新定義處方護理。憑藉其全國認可的臨牀能力和專有平台 LucyIQ™，該公司提供實時洞察，支持基於證據的臨牀決策、清晰的定價和來自美國認證藥劑師的卓越服務。與超過 60,000 家藥房合作，LucyRx 在全國服務超過 4,000 家客户。這是經過精彩重新構想的處方護理。欲瞭解更多信息，請訪問 lucyrx.com。</p>
</div><p><strong>Advisors</strong> Morgan Stanley &amp; Co. LLC is serving as financial advisor to Abarca Health. Pietrantoni Mendez &amp; Alvarez, LLC is serving as lead legal counsel, and Axinn Veltrop &amp; Harkrider LLP is serving as regulatory counsel to Abarca Health.</p>
<div class="lb-trans"><p><strong>顧問</strong> 摩根士丹利 &amp; Co. LLC 擔任 Abarca Health 的財務顧問。Pietrantoni Mendez &amp; Alvarez, LLC 擔任首席法律顧問，Axinn Veltrop &amp; Harkrider LLP 擔任 Abarca Health 的監管顧問。</p>
</div><p>Great Meadows Management, LLC is serving as lead financial advisor to LucyRx. Kirkland &amp; Ellis, LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. are serving as legal counsel to LucyRx.</p>
<div class="lb-trans"><p>Great Meadows Management, LLC 擔任 LucyRx 的首席財務顧問。Kirkland &amp; Ellis, LLP 和 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 擔任 LucyRx 的法律顧問。</p>
</div><p>SOURCE LucyRx; Abarca Health</p>
<div class="lb-trans"><p>來源 LucyRx; Abarca Health</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjE3Jk5ld3NJdGVtSWQ9UEg4NjIwMCZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MTcxNDE4UFJfTkVXU19VU1BSX19fX19QSDg2MjAw" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=PH86200&amp;Transmission_Id=202606171418PR_NEWS_USPR_____PH86200&amp;DateId=20260617"/></p>

14:18 ETAbarca Health and LucyRx Announce Strategic Combination to Create the Only Modern PBM Built for Commercial and Government Scale

prnewswire

摩根士丹利

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

ETAbarca Health 和 LucyRx 宣佈戰略合併，旨在創建唯一一個適用於商業和政府規模的現代藥品福利管理公司（PBM）